Shaanxi Key Laboratory of Brain Disorders & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, Shaanxi, China.
J Drug Target. 2020 Jan;28(1):33-40. doi: 10.1080/1061186X.2019.1616746. Epub 2019 Jun 27.
In patients with cancer, drug tolerance often occurs during the use of chemotherapy drugs, seriously affecting patient prognosis and survival. Therefore, scientists began to study the factors that affect chemotherapy drug sensitivity, and the high correlation between Schlafen-11 (SLFN11) and sensitivity to chemical drugs (mainly DNA-damaging agents, DDAs) has received increasing attention since it was discovered through bioinformatics analyses. Regarding the mechanism, SLFN11 may sensitise cells to chemotherapy drugs by preventing DNA damage repair. In recent years, SLFN11 has gradually become a hot research topic, and the results are enriching our understanding of this molecule. Indeed, the biological functions of SLFN11 under normal physiological conditions and in cancer, changes in its expression levels and mechanisms promoting apoptosis within the context of chemotherapeutic interventions have gradually been uncovered. Studies to date provide knowledge and the experimental and theoretical bases underlying SLFN11 and its effects on sensitivity to chemotherapy drugs. This review summarises the existing research on SLFN11 with the aim of achieving a more comprehensive understanding and furthering the development of strategies to target SLFN11 in the treatment of cancer.
在癌症患者中，化疗药物的使用过程中常常会出现药物耐受，严重影响患者的预后和生存。因此，科学家开始研究影响化疗药物敏感性的因素，SLFN11（ Schlafen-11）与化学药物敏感性（主要是 DNA 损伤剂，DDAs）之间的高度相关性自通过生物信息学分析发现以来，受到了越来越多的关注。关于其机制，SLFN11 可能通过阻止 DNA 损伤修复使细胞对化疗药物敏感。近年来，SLFN11 逐渐成为研究热点，其结果丰富了我们对该分子的认识。事实上，在正常生理条件下和癌症中 SLFN11 的生物学功能、其表达水平的变化以及在化疗干预背景下促进细胞凋亡的机制逐渐被揭示。迄今为止的研究为 SLFN11 及其对化疗药物敏感性的影响提供了知识和实验及理论基础。本综述总结了 SLFN11 的现有研究，旨在更全面地了解它，并进一步制定针对 SLFN11 的策略，以治疗癌症。
